Concepedia

Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG (S0200) phase 3 randomized trial

Maurie Markman, James Moon, Sharon P. Wilczynski, Ana María López, Kendrith M. Rowland, David P. Michelin, Victor J. Lanzotti, Garnet L. Anderson, David S. Alberts

Gynecologic Oncology · 2009 · 57 citations · 10 references

Open access

References

10

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

Medicine, Oncology, Cancer Pharmacology +12

Nonparametric Estimation from Incomplete Observations

Edward L. Kaplan, Paul Meier · Journal of the American Statistical Association · 1958 · 7.8K citations

Public Health, Biostatistics, Mathematics +10

Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan

Alan N. Gordon, John Fleagle, David Guthrie et al. · Journal of Clinical Oncology · 2001 · 1.2K citations

Medicine, Oncology, Pharmacology +16

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial

Mahesh Parmar, Jonathan A. Ledermann, Nicoletta Colombo et al. · The Lancet · 2003 · 1.2K citations

Medicine, Gynecology, Oncology +17

A Confidence Interval for the Median Survival Time

Ron Brookmeyer, John Crowley · Biometrics · 1982 · 908 citations

Public Health, Biostatistics, Clinical Epidemiology +16